Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 avr. 2026 17h05 HE | Source: Barrick Mining Corporation

Barrick Provides an Update on Reko Diq

All amounts expressed in U.S. dollars TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Barrick Mining Corporation (NYSE:B)(TSX:ABX) (“Barrick” or the “Company”) today provides an update on the status of...
02 avr. 2026 12h30 HE | Source: GENFIT S.A.

GENFIT : Résultats financiers annuels 2025 et point sur les activités de la Société

Faits financiers marquants de 2025 : Trésorerie et équivalents de trésorerie s’élevant à 101.1 millions d’euros au 31 décembre 2025 Chiffre d’affaires s’élevant à 65.4 millions d’euros au 31 décembre...
02 avr. 2026 12h30 HE | Source: GENFIT S.A.

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

2025 financial highlights: Cash and cash equivalents totaled €101.1 million as of December 31, 2025Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million...
02 avr. 2026 11h45 HE | Source: Transgene S.A.

Transgene et NEC Bio signent un accord de licence pour préparer les prochaines étapes de développement de TG4050 dans les cancers de la tête et du cou

Transgene et NEC Bio signent un accord de licence pour préparer les prochaines étapes de développement de TG4050 dans les cancers de la tête et du cou
02 avr. 2026 11h45 HE | Source: Transgene S.A.

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
02 avr. 2026 10h24 HE | Source: Faruqi & Faruqi LLP

IBRX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their Options If you purchased or...
02 avr. 2026 08h45 HE | Source: Entera Bio Ltd.

Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds

TEL AVIV, Israel, April 02, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that it has entered...
02 avr. 2026 07h05 HE | Source: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune...
02 avr. 2026 07h01 HE | Source: Adagene Inc.

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide...
02 avr. 2026 07h00 HE | Source: Skye Bioscience, Inc.

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other...

Page suivante